Exane Derivatives’s Halliburton HAL Stock Holding History

Exane Derivatives’s Portfolio HAL Stock Details HAL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-600	Closed	-$3K	–	552
2015 Q2	$3K	Hold	600	–	–	﹤0.01%	406
2015 Q1	$39K	Buy	+600	New	+$25K	﹤0.01%	331

Other funds holding HAL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pzena Investment Management New York $30.8B AUM 11.29% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Exane Derivatives's HAL Position: Q2 2022 in Review

Exane Derivatives sold out of Halliburton (HAL) in Q2 2022, closing a stake of 9,790 shares — an estimated $371K sold.

Exane Derivatives first reported a position in HAL in Q4 2014 and held it in 23 quarters. The position peaked at $3.82M in Q2 2019. 841 funds tracked by Wall St. Rank hold HAL as of Q2 2022.

Exane Derivatives reported no remaining Halliburton position as of Q2 2022 after selling out during the quarter.
Exane Derivatives sold 9,790 Halliburton shares in Q2 2022, an estimated $371K.
Exane Derivatives first reported a position in Halliburton in Q4 2014 and held it in 23 quarters.
Exane Derivatives's Halliburton position peaked at $3.82M in Q2 2019.
841 funds tracked by Wall St. Rank held Halliburton as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.